中國同輻(01763.HK):放棄行使中核租賃增資優先認購權
格隆匯8月31日丨中國同輻(01763.HK)公吿,於2023年8月31日,公司、中核資本、中國核電、新華髮電、其他股東及中核租賃訂立增資協議,據此,中核租賃擬增資人民幣18億元,其中由中核資本出資人民幣10億元,中國核電出資人民幣5億元,新華髮電出資人民幣3億元,公司及其他股東不進行出資。
根據中國公司法,公司作為中核租賃的股東,在中核租賃增資時,有權優先按照實繳出資比例認購出資(全體股東約定不按照實繳出資比例優先認購出資的除外),據此,公司對中核租賃的增資享有優先認購權。經綜合考慮本次增資的交易背景以及集團整體發展規劃方向等因素後,公司放棄行使對中核租賃增資優先認購權。本次增資完成後,中核租賃仍為公司參股公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.